Summary: Autism spectrum disorder (ASD) involves more than 100 genes, making a single universal drug unlikely. Researchers at Yale used larval zebrafish to build a “pharmaco-behavioral” map that links drug-induced behavioral signatures with genetic forms of autism to find candidate treatments.
In the study, the team screened 774 U.S. Food and Drug Administration (FDA)-approved drugs for their effects on larval zebrafish behavior. By matching each drug’s behavioral “fingerprint” to the sleep and sensory-processing disruptions caused by mutations in autism risk genes such as SCN2A and DYRK1A, they identified promising compounds — notably levocarnitine — that reverse or “rescue” those altered behaviors.
Key Facts
- Behavioral fingerprints: The team defined specific sleep and sensory-processing abnormalities in zebrafish that carry high-impact autism risk genes.
- Repurposing FDA-approved drugs: From screening 774 approved drugs, researchers produced a curated database of 520 non-toxic compounds with reproducible effects on zebrafish behavior that can be evaluated for precision applications.
- Levocarnitine as a lead candidate: Levocarnitine, a molecule involved in fatty acid transport into mitochondria, emerged as a top rescuer for phenotypes linked to mutations in SCN2A and DYRK1A.
- Cross-species validation: The rescuing effect of levocarnitine was reproduced in human pluripotent stem cell–derived excitatory neurons carrying the same mutations, where it corrected network activity deficits.
- Open resource: Yale created a searchable, open database of the behavioral profiles from the drug screen to accelerate further discovery across labs and genetic models.
Source: Yale
Why zebrafish? Over the past decades, zebrafish have become a powerful model for studying human diseases. Their genetic similarity to humans, ease of genetic manipulation, high fecundity, and transparent larvae make them ideal for scalable behavioral and drug screens. These attributes let researchers observe how specific genetic changes alter sleep, movement, and sensory responses across large numbers of animals.
Yale researchers applied these strengths to ASD research with a precision-medicine approach: rather than searching for a single drug that treats all autism, they grouped autism risk genes by shared behavioral effects and looked for drugs whose behavioral signatures oppose those gene-associated disruptions.
Using automated assays, the team first profiled behavior in wild-type larval zebrafish after exposing them to 774 FDA-approved compounds. Statistical modeling identified 520 compounds that were non-toxic and produced significant, quantifiable changes in basic arousal and sensory behaviors. These drug-induced profiles formed the core database for comparison against gene-specific behavioral signatures.
Next, the researchers compared the drug profiles to behavioral fingerprints previously mapped for nine high-impact autism genes. This pharmaco-behavioral profiling strategy prioritizes drugs whose effects anticorrelate with — or oppose — the abnormal behaviors caused by a particular gene mutation. The approach led the team to test selected candidates in zebrafish mutants for SCN2A and DYRK1A.
Three main discoveries emerged. First, several drugs were found that specifically rescue sleep and sensory-processing abnormalities tied to particular autism genes. These rescue compounds implicate biological pathways such as estrogen signaling, microtubule dynamics, mitochondrial function, and lipid metabolism as relevant to distinct genetic subgroups of ASD.
Second, levocarnitine was identified as a top rescue compound for both SCN2A and DYRK1A mutants. In zebrafish, levocarnitine corrected dysregulated behaviors, restored disrupted lipid metabolic pathways, and normalized regional brain activity differences measured at baseline.
Third, the rescuing effect translated to human cells: levocarnitine improved network activity in human pluripotent stem cell–derived glutamatergic neurons carrying mutations in these same genes, supporting conservation of the drug’s mechanism across species and experimental systems.
To support wider discovery efforts, the team published the behavioral profiles of all 774 screened drugs in an open, searchable resource. This pharmaco-behavioral database is intended to guide future screens and identify additional drug candidates for specific genetic subtypes of autism.
“ASD is clinically and genetically diverse, so precision strategies that subgroup risk genes will be essential to find effective treatments,” said Ellen J. Hoffman, associate professor at the Yale Child Study Center and senior author. “Our pharmaco-behavioral platform provides a scalable path to nominate targeted therapies for individuals with particular genetic changes.”
The multidisciplinary team includes experts in biostatistics, psychiatry, stem cell biology, and neuroscience. Funding came from multiple public and private sources supporting translational research in neurodevelopmental disorders.
Key Questions Answered:
A: Zebrafish share roughly 70% of their genes with humans and show conserved brain development. Their transparent larvae and ease of genetic manipulation let researchers observe how single genes affect sleep, movement, and light sensitivity across large samples, enabling high-throughput hypothesis testing.
A: Pharmaco-behavioral profiling compares the behavioral effects of drugs in healthy animals to the behavioral disruptions caused by specific gene mutations. A drug whose effects oppose a gene-linked abnormality is a candidate “rescuer,” much like fitting a key to a lock to restore normal function.
A: Not immediately. Positive results in zebrafish and human-derived neurons are promising, but clinical trials are required. The likely path is targeted trials for individuals with specific mutations, such as SCN2A, where levocarnitine may offer benefit under a precision-medicine framework.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by staff.
- Additional context was provided by editorial staff.
About this autism and genetics research news
Author: Fred Mamoun
Source: Yale
Contact: Fred Mamoun – Yale
Image: Image credited to Neuroscience News
Original Research: Open access. “Pharmaco-behavioral profiling identifies suppressors of autism gene–associated phenotypes in zebrafish” by Priyanka Jamadagni et al., PNAS. DOI:10.1073/pnas.2518846123
Abstract
Pharmaco-behavioral profiling identifies suppressors of autism gene–associated phenotypes in zebrafish
High-throughput pharmaco-behavioral screens in scalable in vivo systems provide a powerful route for drug discovery related to large-effect autism spectrum disorder genes. This study establishes a database and open website documenting the behavioral signatures of 520 FDA-approved drugs using automated assays of sensory processing and arousal in larval zebrafish.
By leveraging behavioral profiles from nine large-effect ASD gene mutants, the researchers identified pharmacological mechanisms that anticorrelate with subgroups of ASD genes sharing behavioral phenotypes. Targeted screening in SCN2A and DYRK1A mutants uncovered compounds that suppress mutant phenotypes, including estropipate (an estrogen receptor agonist), paclitaxel (a microtubule inhibitor), and levocarnitine (a mitochondrial modulator).
Levocarnitine rescued regional brain-activity deficits and corrected dysregulated lipid metabolism in mutants, and it improved signaling in human pluripotent stem cell–derived glutamatergic neurons with the same gene mutations. Overall, this pharmaco-behavioral resource supports precision medicine approaches to identify targets relevant to high-impact ASD genes.